{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:11:27Z","timestamp":1785795087329,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Project of Medical Research of Xi'an Science and Technology Bureau","award":["2024JH-YXZD-0069"],"award-info":[{"award-number":["2024JH-YXZD-0069"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15105-9","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:52:34Z","timestamp":1765810354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The incidence and risk factors of pulmonary infection complications in lung cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1186","volume":"25","author":[{"given":"Haixia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxuan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosha","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"1","key":"15105_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"15105_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030320","volume":"11","author":"S Tang","year":"2022","unstructured":"Tang S, Qin C, Hu H, Liu T, He Y, Guo H, et al. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells. 2022;11(3):320.","journal-title":"Cells"},{"issue":"8","key":"15105_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s11864-022-00989-7","volume":"23","author":"B Schlick","year":"2022","unstructured":"Schlick B, Shields MD, Marin-Acevedo JA, Patel I, Pellini B. Immune checkpoint inhibitors and chemoradiation for limited-stage small cell lung cancer. Curr Treat Options Oncol. 2022;23(8):1104\u201320.","journal-title":"Curr Treat Options Oncol"},{"key":"15105_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663986","volume":"12","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Tang L, Zhou Y, He W, Li W. Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management. Front Immunol. 2021;12:663986.","journal-title":"Front Immunol"},{"issue":"11","key":"15105_CR5","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1159\/000526141","volume":"101","author":"P Zhou","year":"2022","unstructured":"Zhou P, Zhao X, Wang G. Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: a systemic review and meta-analysis. Respiration. 2022;101(11):1035\u201350.","journal-title":"Respiration"},{"issue":"6","key":"15105_CR6","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.21873\/invivo.13346","volume":"37","author":"M Papadakis","year":"2023","unstructured":"Papadakis M, Karniadakis I, Mazonakis N, Akinosoglou K, Tsioutis C, Spernovasilis N. Immune checkpoint inhibitors and infection: what is the interplay? In Vivo. 2023;37(6):2409\u201320.","journal-title":"In Vivo"},{"issue":"4","key":"15105_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CJI.0000000000000504","volume":"47","author":"YS Jeung","year":"2024","unstructured":"Jeung YS, Chun JY, Choi BK, Park SY, Lim HJ, Park JW, et al. Infection-related hospitalizations during immune checkpoint inhibitor treatment without immunosuppressants. J Immunother. 2024;47(4):139\u201347.","journal-title":"J Immunother"},{"key":"15105_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1138483","volume":"14","author":"X Guo","year":"2023","unstructured":"Guo X, Chen S, Wang X, Liu X. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: diagnosis, mechanism, and treatment strategies. Front Immunol. 2023;14:1138483.","journal-title":"Front Immunol"},{"issue":"1","key":"15105_CR9","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S1470-2045(19)30674-6","volume":"21","author":"EA Langan","year":"2020","unstructured":"Langan EA, Graetz V, Allerheiligen J, Zillikens D, Rupp J, Terheyden P. Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. Lancet Oncol. 2020;21(1):e55-65.","journal-title":"Lancet Oncol"},{"issue":"11","key":"15105_CR10","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1093\/cid\/ciw539","volume":"63","author":"M Del Castillo","year":"2016","unstructured":"Del Castillo M, Romero FA, Arg\u00fcello E, Kyi C, Postow MA, Redelman-Sidi G. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis. 2016;63(11):1490\u20133.","journal-title":"Clin Infect Dis"},{"key":"15105_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2020.09.025","volume":"141","author":"JD Karam","year":"2020","unstructured":"Karam JD, Noel N, Voisin AL, Lanoy E, Michot JM, Lambotte O. Infectious complications in patients treated with immune checkpoint inhibitors. Eur J Cancer. 2020;141:137\u201342.","journal-title":"Eur J Cancer"},{"key":"15105_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","volume":"146","author":"K Fujita","year":"2019","unstructured":"Fujita K, Kim YH, Kanai O, Yoshida H, Mio T, Hirai T. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respir Med. 2019;146:66\u201370.","journal-title":"Respir Med"},{"issue":"6","key":"15105_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab187","volume":"8","author":"DF Bavaro","year":"2021","unstructured":"Bavaro DF, Pizzutilo P, Catino A, Signorile F, Pesola F, Di Gennaro F, et al. Incidence of infections and predictors of mortality during checkpoint inhibitor immunotherapy in patients with advanced lung cancer: a retrospective cohort study. Open Forum Infect Dis. 2021;8(6):ofab187.","journal-title":"Open Forum Infect Dis"},{"key":"15105_CR14","unstructured":"Tuberculosis Classification. (WS196-2017).People\u2019s Republic of China state health and Family Planning Commission."},{"key":"15105_CR15","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2009."},{"issue":"5","key":"15105_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497\u2013530.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3 Suppl","key":"15105_CR17","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15105_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.828858","volume":"12","author":"J Bi","year":"2021","unstructured":"Bi J, Qian J, Yang D, Sun L, Lin S, Li Y, et al. Dosimetric risk factors for acute radiation pneumonitis in patients with prior receipt of immune checkpoint inhibitors. Front Immunol. 2021;12:828858.","journal-title":"Front Immunol"},{"issue":"1","key":"15105_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cam4.4393","volume":"11","author":"JA Ross","year":"2022","unstructured":"Ross JA, Komoda K, Pal S, Dickter J, Salgia R, Dadwal S. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022;11(1):21\u20137.","journal-title":"Cancer Med"},{"issue":"7","key":"15105_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cllc.2023.06.011","volume":"24","author":"MZ Guo","year":"2023","unstructured":"Guo MZ, Balaji A, Murray JC, Reuss JE, Steinke SM, Bennett K, et al. Infectious complications in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Clin Lung Cancer. 2023;24(7):613\u201320.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"15105_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13743-7","volume":"25","author":"X Wang","year":"2025","unstructured":"Wang X, Wu YX, Hu WP, Zhang J. Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy. BMC Cancer. 2025;25(1):307.","journal-title":"BMC Cancer"},{"key":"15105_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018202","volume":"13","author":"S Wurster","year":"2022","unstructured":"Wurster S, Watowich SS, Kontoyiannis DP. Checkpoint inhibitors as immunotherapy for fungal infections: promises, challenges, and unanswered questions. Front Immunol. 2022;13:1018202.","journal-title":"Front Immunol"},{"issue":"7","key":"15105_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.6004\/jnccn.2022.7020","volume":"20","author":"NJ Shah","year":"2022","unstructured":"Shah NJ, Cook MR, Wu T, Lev-Ari S, Blackburn MJ, Serzan MT, et al. The risk of opportunistic infections and the role of antibiotic prophylaxis in patients on checkpoint inhibitors requiring steroids. J Natl Compr Cancer Network: JNCCN. 2022;20(7):800\u2013e807801.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"12","key":"15105_CR24","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","volume":"11","author":"K Fujita","year":"2016","unstructured":"Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J Thorac Oncol. 2016;11(12):2238\u201340.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"15105_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa126","volume":"7","author":"K Fujita","year":"2020","unstructured":"Fujita K, Yamamoto Y, Kanai O, Okamura M, Hashimoto M, Nakatani K, et al. Incidence of active tuberculosis in lung cancer patients receiving immune checkpoint inhibitors. Open Forum Infect Dis. 2020;7(5):ofaa126.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"15105_CR26","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s00262-022-03198-1","volume":"71","author":"K Fujita","year":"2022","unstructured":"Fujita K, Elkington P, Redelman-Sidi G, Kanai O, Yamamoto Y, Imakita T, et al. Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study. Cancer Immunol Immunother. 2022;71(11):2757\u201364.","journal-title":"Cancer Immunol Immunother"},{"key":"15105_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2020.03.015","volume":"132","author":"J Zaemes","year":"2020","unstructured":"Zaemes J, Kim C. Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature. Eur J Cancer. 2020;132:168\u201375.","journal-title":"Eur J Cancer"},{"issue":"4","key":"15105_CR28","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1093\/oncolo\/oyad340","volume":"29","author":"HW Chen","year":"2024","unstructured":"Chen HW, Kuo YW, Chen CY, Chang CH, Wang SM, Chien YC, et al. Increased tuberculosis reactivation risk in patients receiving immune checkpoint Inhibitor-Based therapy. Oncologist. 2024;29(4):e498\u2013506.","journal-title":"Oncologist"},{"issue":"3","key":"15105_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","volume":"77","author":"T Morelli","year":"2022","unstructured":"Morelli T, Fujita K, Redelman-Sidi G, Elkington PT. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2022;77(3):304\u201311.","journal-title":"Thorax"},{"key":"15105_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.918787","volume":"13","author":"X Lu","year":"2022","unstructured":"Lu X, Wang J, Zhang T, Zhou Z, Deng L, Wang X, et al. Comprehensive pneumonitis profile of thoracic radiotherapy followed by immune checkpoint inhibitor and risk factors for radiation recall pneumonitis in lung cancer. Front Immunol. 2022;13:918787.","journal-title":"Front Immunol"},{"key":"15105_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110047","volume":"190","author":"T Nie","year":"2024","unstructured":"Nie T, Chen Z, Cai J, Ai S, Xue X, Yuan M, et al. Integration of dosimetric parameters, clinical factors, and radiomics to predict symptomatic radiation pneumonitis in lung cancer patients undergoing combined immunotherapy and radiotherapy. Radiother Oncol. 2024;190:110047.","journal-title":"Radiother Oncol"},{"key":"15105_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.02.011","author":"L Xiao","year":"2025","unstructured":"Xiao L, Li Y, Wang S, Fan L, Li Q, Fan Z, et al. Early prediction of radiation pneumonitis in patients with lung cancer treated with immunotherapy through monitoring of plasma chemokines. Int J Radiat Oncol Biol Phys. 2025. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.02.011.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"15105_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41564-022-01172-2","volume":"7","author":"M Hoenigl","year":"2022","unstructured":"Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127\u201340.","journal-title":"Nat Microbiol"},{"issue":"10","key":"15105_CR34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/S1470-2045(08)70255-9","volume":"9","author":"S Vento","year":"2008","unstructured":"Vento S, Cainelli F, Temesgen Z. Lung infections after cancer chemotherapy. Lancet Oncol. 2008;9(10):982\u201392.","journal-title":"Lancet Oncol"},{"key":"15105_CR35","unstructured":"Chen J, Liu Y, Cai H, Zheng W. Risk factors for pulmonary infection in patients with non-small cell lung cancer: a Meta-analysis."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15105-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15105-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15105-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:52:35Z","timestamp":1765810355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15105-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15105"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15105-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Northwest University Affiliated Chest Hospital (Approval No. R2024-007-01),and informed consent forms were obtained from all patients prior to their participation in this study. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1871"}}